The FDA on Thursday approved a Sunovion Pharmaceuticals treatment for Parkinson’s disease, giving patients a new way to take an old drug.
The Sunovion product, Kynmobi, is a formulation of apomorphine hydrochloride, a drug that treats “off” episodes experienced by Parkinson’s patients. These are times when the standard of care drug, levodopa, wears off and tremors, stiffness, and other symptoms return. Apomorphine can be administered in several different ways. The Sunovion product is the first sublingual formulation of apomorphine approved by the FDA.
UNDERWRITERS AND PARTNERS